

W24: Neuromodulation in the Management of Lower Urinary Tract Dysfunction: Current Best Practice, Innovation and the Future

Workshop Chair: Arun Sahai, United Kingdom

Time	Topic	Speakers
10	Introduction and insights into mechanism of action	Arun Sahai Sachin Malde
10	Neuromodulation for refractory OAB	Sachin Malde
10	Neuromodulation for voiding dysfunction	Roger Dmochowski
10	Neuromodulation for neurogenic lower urinary tract dysfunction	Marcio Averbeck
10	Neuromodulation for bladder pain / interstitial cystitis / chronic pelvic pain syndrome	Arun Sahai
10	Optimising Neuromodulation: Patient Selection, Urodynamics and Programming	Arun Sahai
10	New Technologies, Innovations and the Future	Marcio Averbeck

Aims of Workshop

Sacral Neuromodulation (SNM) has had FDA approval for the management of overactive bladder (OAB) and chronic non-obstructive urinary retention for greater than 20 years. Since then posterior tibial nerve stimulation was introduced and predominantly is used to treat refractory OAB. In recent years several innovative developments have taken place in this field with additional benefits. The purpose of this workshop is to review the current status of neuromodulation in managing lower urinary tract dysfunction with a particular focus on evidence published in the last 5-10 years, discuss ways of optimising neuromodulation for the benefit of patients, discuss the new innovations and where the technology is heading in the future.

Learning Objectives

Understand the current evidence base for neuromodulation (sacral, tibial) in managing lower urinary tract dysfunction (OAB, chronic non-obstructive retention, neurogenic and bladder/pelvic pain)

Target Audience

Urology, Urogynaecology and Female & Functional Urology, Basic Science

Advanced/Basic

Intermediate

Suggested Learning before Workshop Attendance

International Continence Society best practice statement for use of sacral neuromodulation.

Goldman HB, Lloyd JC, Noblett KL, Carey MP, Castaño Botero JC, Gajewski JB, Lehur PA, Hassouna MM, Matzel KE, Paquette IM, de Wachter S, Ehlert MJ, Chartier-Kastler E, Siegel SW.

Neurourol Urodyn. 2018 Jun;37(5):1823-1848. doi: 10.1002/nau.23515. Epub 2018 Apr 11.

How can we better manage drug-resistant OAB/DO? ICI-RS 2018.

Chermansky C, Schurch B, Rahnama'i MS, Averbeck MA, Malde S, Mancini V, Valentini F, Sahai A.

Neurourol Urodyn. 2019 Dec;38 Suppl 5:S46-S55. doi: 10.1002/nau.24055. Review.

What Is New in Neuromodulation for Overactive Bladder?

Tutolo M, Ammirati E, Van der Aa F.

Eur Urol Focus. 2018 Jan;4(1):49-53. doi: 10.1016/j.euf.2018.04.019. Review.